Ryanodine stabilizers / fast skeletal muscle troponin activators
Muscle & Strength · Muscle contractility modulator
Tier D
High-risk evidence profile
Bottom line
Read Off Label grades Ryanodine stabilizers / fast skeletal muscle troponin activators as D (3.1/10) based on preclinical-weak evidence, unclear benefit magnitude, and a unknown-high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 3/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
WADA coverage: ryanodine receptor-1-calstabin complex stabilizers, S-107, S48168/ARM210, troponin activators, reldesemtiv and tirasemtiv.
Studied, labeled, or reported-use context: No approved performance dose — Investigational/not approved for performance; WADA S0 prohibited; not individualized guidance.
What the evidence says
WADA coverage: ryanodine receptor-1-calstabin complex stabilizers, S-107, S48168/ARM210, troponin activators, reldesemtiv and tirasemtiv. Included as perceived muscle-performance enhancers, not established healthspan tools.
Mechanism
These agents target calcium leak or fast skeletal muscle troponin activation to improve contractile function or fatigue resistance, mostly in neuromuscular-disease development programs.
Studied, labeled, or reported dose & route
No approved performance dose
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Ryanodine stabilizers / fast skeletal muscle troponin activators's effects?
- Read Off Label rates the evidence for Ryanodine stabilizers / fast skeletal muscle troponin activators as Preclinical-Weak and the benefit magnitude as unclear, producing an overall grade of D (3.1/10). WADA coverage: ryanodine receptor-1-calstabin complex stabilizers, S-107, S48168/ARM210, troponin activators, reldesemtiv and tirasemtiv.
- What safety findings are reported for Ryanodine stabilizers / fast skeletal muscle troponin activators?
- Ryanodine stabilizers / fast skeletal muscle troponin activators has a unknown-high risk profile in the database. Unknown-High (limited human safety data for off-label performance use) Legal status: Investigational/not approved for performance; WADA S0 prohibited.
- What does the low Safety score for Ryanodine stabilizers / fast skeletal muscle troponin activators represent?
- The Safety score is 3/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for Ryanodine stabilizers / fast skeletal muscle troponin activators?
- No approved performance dose This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Ryanodine stabilizers / fast skeletal muscle troponin activators work?
- These agents target calcium leak or fast skeletal muscle troponin activation to improve contractile function or fatigue resistance, mostly in neuromuscular-disease development programs.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.